Thymosin Alpha-1
Well Researched
Thymosin Alpha-1 (Ta1) is a synthetic version of a 28-amino acid peptide your thymus gland naturally produces. Your thymus is the organ that trains your immune cells, and it shrinks as you age. Ta1 has been studied in over 11,000 patients across 30+ clinical trials, holds FDA orphan drug designations for four conditions, and is approved in 35+ countries. It has a strong safety record, with less than 1% serious adverse events across all those trials.
How it works
Ta1 works by activating and training several types of immune cells. It helps immature T-cells develop into fully functional defenders, boosts the activity of natural killer (NK) cells that patrol for infections and abnormal cells, and improves how your immune system's "scout" cells identify and respond to threats. Think of it as a tune-up for your immune system: it does not just crank up the volume, it helps each part work more effectively.
Key benefits
- ✓Strengthens overall immune function by activating T-cells and natural killer cells
- ✓Studied extensively across 30+ clinical trials with a strong safety profile
- ✓Approved in 35+ countries for immune support, with four FDA orphan drug designations
- ✓Helps rebalance immune responses rather than simply boosting them
Related goals
Protocols
| Protocol | Dose | Frequency |
|---|---|---|
| Standard immune support | 1.6mg | 2x weekly |
| Acute conditions (sepsis) | 1.6mg | 2x daily x 5 days, then daily |
| Cancer/hepatitis support | 1.6mg | 2x weekly |
| Maintenance/prevention | 1.6mg | 2x weekly |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What to expect
Initial immune system activation begins
Enhanced immune function and reduced infection risk
Full immune-balancing benefits reached
Sustained immune support with continued use
What to know
- ⚠Strong safety profile with less than 1% serious adverse events across 11,000+ patients studied
- ⚠Most common side effect: mild injection site reactions (under 10%)
- ⚠Contraindicated in organ transplant recipients (risk of graft rejection)
- ⚠Monitor for hypersensitivity reactions with first dose
- ⚠Not recommended during pregnancy or breastfeeding